Pain Therapeutics (NASDAQ:PTIE) saw unusually-strong trading volume on Monday . Approximately 403,089 shares were traded during trading, an increase of 82% from the previous session’s volume of 221,465 shares.The stock last traded at $2.51 and had previously closed at $2.54.

Several equities analysts recently issued reports on PTIE shares. Zacks Investment Research raised shares of Pain Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 31st. Gabelli lowered shares of Pain Therapeutics from a “buy” rating to a “hold” rating and set a $2.50 price objective on the stock. in a report on Tuesday, September 13th.

The stock’s 50-day moving average is $2.49 and its 200 day moving average is $2.32. The firm’s market cap is $129.19 million.

Pain Therapeutics (NASDAQ:PTIE) last posted its earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.07. On average, equities research analysts predict that Pain Therapeutics will post ($0.46) EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. Bridgeway Capital Management Inc. raised its position in Pain Therapeutics by 29.8% in the second quarter. Bridgeway Capital Management Inc. now owns 435,853 shares of the biopharmaceutical company’s stock valued at $955,000 after buying an additional 100,000 shares during the last quarter. Vanguard Group Inc. raised its position in Pain Therapeutics by 3.3% in the second quarter. Vanguard Group Inc. now owns 1,454,358 shares of the biopharmaceutical company’s stock valued at $3,185,000 after buying an additional 46,804 shares during the last quarter. First Eagle Investment Management LLC raised its position in Pain Therapeutics by 16.2% in the second quarter. First Eagle Investment Management LLC now owns 6,602,658 shares of the biopharmaceutical company’s stock valued at $14,460,000 after buying an additional 918,148 shares during the last quarter. Brandes Investment Partners LP raised its position in Pain Therapeutics by 108.8% in the second quarter. Brandes Investment Partners LP now owns 78,758 shares of the biopharmaceutical company’s stock valued at $172,000 after buying an additional 41,039 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in Pain Therapeutics by 0.7% in the second quarter. Acadian Asset Management LLC now owns 351,072 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 2,471 shares during the last quarter. Institutional investors own 55.07% of the company’s stock.

Pain Therapeutics Company Profile

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

5 Day Chart for NASDAQ:PTIE

Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.